

# A current evaluation of hypo pharyngeal carcinoma.

Pape Debaene\*

Department of Surgery, University hospital of Poitiers, France

## Abstract

**A small percentage of all head and neck cancers, or about 3%, are hypo pharyngeal malignancies. With a reported 5-year overall survival rate of about 30–35%, hypo pharyngeal carcinoma has one of the worst prognoses of all head and neck malignancies. Therapy-related toxicity and the requirement for surgical salvage continue to rule this disease's landscape. With an emphasis on the development of an organ sparing paradigm, we set out to present a thorough overview of the existing management concepts, recent literature, and evidence-based therapeutic choices surrounding treatment for hypo pharyngeal squamous cell carcinoma in this.**

**Keywords:** Hypo pharyngeal cancer, Carcinoma, Cell carcinoma, Radiotherapy.

## Introduction

Hypopharyngeal carcinoma makes up about 3% of all head and neck cancers, making it a relatively uncommon disease. Unfortunately, of all head and neck malignancies, hypopharyngeal carcinoma has one of the worst prognoses, with a reported 5-year overall survival rate of about 30–35%. Anatomically, the lateral pharynx, posterior pharyngeal wall, piriform sinuses, and post-cricoid region leading to the esophageal entrance are the subsites of the hypopharynx that are frequently used to characterise it. Hypopharyngeal malignancies frequently emerge at an advanced stage in clinical practise, necessitating rigorous treatment plans that have a significant negative impact on a patient's quality of life. Despite improvements in head and neck cancer treatment overall, prognosis for hypopharyngeal carcinoma have remained subpar and have shown just a small gain in survival over time. Nearly 50% of patients experience recurrence within the first year after diagnosis, and many of them are found to have distant metastases. Treatment for hypopharyngeal carcinoma is still difficult, and creating the best treatment plan calls for a multidisciplinary approach. From an oncological perspective, the main objective is to maximise survival and enable functional organ preservation wherever possible.

## Clinical and physiological epidemiology

The vast majority of malignancies in the hypopharynx are squamous cell carcinomas. Most Hypopharyngeal Squamous Cell Carcinoma (HSCC) patients are male, and 90% of them have a history of smoking or drinking heavily. According to epidemiologic data from the National Carcinoma Database (NCDB), patients with hypopharyngeal cancer are typically over 70 percent Caucasian, 75% male and average age 63. Until laryngeal invasion or nodal metastases, hypopharyngeal

tumours may not show any symptoms. Early illness symptoms are vague and can mimic harmless disorders like laryngopharyngeal reflux or Globus feeling. Flexible fiberoptic laryngoscopy exams struggle to detect tumours located within the piriform sinus, and regular imaging methods like Computed Tomography (CT) or magnetic resonance imaging can miss them.

Accurate staging and early identification are crucial for managing hypopharyngeal cancer. As with other head and neck malignancies, a thorough history and physical examination, as well as a head and neck exam that includes a flexible fiberoptic laryngoscopy, are recommended. As was already indicated, if there is a clinical suspicion of hypopharyngeal cancer, a fiberoptic laryngoscopy exam may not be sufficient. Depending on the clinical stage and co-morbid disorders, surgery, Radiation Therapy (RT), or chemotherapy may be used as possible treatments for HSCC. The current NCCN recommendations include a variety of surgical and non-surgical treatment options and are classified by the viability of surgical resection for the main tumour. There isn't a clear favourite primary treatment modality, though. Single modality therapy is often saved for certain early stage diseases.

## Conclusion

High-quality evidence is available to support a number of non-surgical chemo radiotherapy regimens that allow for laryngeal preservation in advanced stages hypopharyngeal squamous cell carcinoma. It is important to note that the bulk of evidence-based medicine trials on laryngeal preservation involve a diverse patient population with primary malignancies of the larynx and hypopharynx. As a result, clinical studies tailored specifically for hypopharyngeal carcinoma.

\*Correspondence to: Pape Debaene, Department of Surgery, University hospital of Poitiers, France, E-mail: pape@deb.fr

Received: 30-January-2023, Manuscript No. AACCR-23-80651; Editor assigned: 02-February-2023, PreQC No. AACCR-23-80651(PQ); Reviewed: 16-February-2023, QC No. AACCR-23-80651; Revised: 21-Feb-2023, Manuscript No. AACCR-23-80651(R); Published: 28-Feb-2023, DOI:10.35841/aacr-6.1.135

## References

1. Park YM, Kim WS, Byeon HK, et al. Feasibility of transoral robotic hypopharyngectomy for early-stage hypopharyngeal carcinoma. *Oral Oncol.* 2010;46(8):597-602.
2. Machtay M, Moughan J, Farach A, et al. Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: An RTOG analysis. *Int J Radiat Oncol Biol Phys.* 2012;84(4):983-9.
3. De Figueiredo BH, Fortpied C, Menis J, et al. Long-term update of the 24954 EORTC phase III trial on larynx preservation. *Eur J Cancer.* 2016;65:109-12.
4. Kotwall C, Sako K, Razack MS, et al. Metastatic patterns in squamous cell cancer of the head and neck. *Am J Surg.* 1987; 154(4):439-42.
5. Eckel HE, Staar S, Volling P, et al. Surgical treatment for hypopharynx carcinoma: feasibility, mortality, and results. *Otolaryngol Head Neck Surg.* 2001;124(5):561-9.

**Citation:** Debaene P. A current evaluation of hypo pharyngeal carcinoma. *J Can Clinical Res.* 2023;6(1):135